|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2010-7-30
|
|
pubmed:abstractText |
Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy that is dependent on both tumor context and treatment duration. We aimed to characterize this activity and to evaluate the effects of discontinuation of treatment on the dynamics of tumor regrowth.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BagriAnilA,
pubmed-author:BerryLeanneL,
pubmed-author:DamicoLisa ALA,
pubmed-author:FuhGermaineG,
pubmed-author:GunterBertB,
pubmed-author:HollisterBethB,
pubmed-author:KasmanIanI,
pubmed-author:PlowmanGreg DGD,
pubmed-author:RosenOliverO,
pubmed-author:SchmidtMaikeM,
pubmed-author:SinghMallikaM,
pubmed-author:XiangHongH
|
|
pubmed:copyrightInfo |
(c) 2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3887-900
|
|
pubmed:meshHeading |
pubmed-meshheading:20554752-Angiogenesis Inhibitors,
pubmed-meshheading:20554752-Animals,
pubmed-meshheading:20554752-Antibodies, Monoclonal,
pubmed-meshheading:20554752-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20554752-Cell Line, Tumor,
pubmed-meshheading:20554752-Cross Reactions,
pubmed-meshheading:20554752-Humans,
pubmed-meshheading:20554752-Mice,
pubmed-meshheading:20554752-Neoplasms, Experimental,
pubmed-meshheading:20554752-Neovascularization, Pathologic,
pubmed-meshheading:20554752-Treatment Outcome,
pubmed-meshheading:20554752-Vascular Endothelial Growth Factor A,
pubmed-meshheading:20554752-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
|
|
pubmed:affiliation |
Department of Tumor Biology and Angiogenesis, Genentech Inc., South San Francisco, CA 94080, USA. abagri@gene.com
|
|
pubmed:publicationType |
Journal Article
|
